Here, we used BRAFV600E mutant melanoma models with defined YAP1 activity to identify a clinically relevant subgroup of MAPK pathway inhibitor (MAPKi)-resistant melanoma characterized by high YAP1 activity. Here, YAP1 is linked to melanoma.